Knockdown of GSG2 inhibits prostate cancer progression in vitro and in vivo

Yu,Feng; Lin,Yuanyuan; Xu,Xinping; Liu,Weipeng; Tang,Dan; Zhou,Xiaochen; Wang,Gongxian; Zheng,Yi; Xie,An

doi:10.3892/ijo.2020.5043

Knockdown of GSG2 inhibits prostate cancer progression in vitro and in vivo

Authors:
- Feng Yu
- Yuanyuan Lin
- Xinping Xu
- Weipeng Liu
- Dan Tang
- Xiaochen Zhou
- Gongxian Wang
- Yi Zheng
- An Xie
View Affiliations

Affiliations: Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Department of Hematology, Jiangxi Provincial Children's Hospital, Nanchang, Jiangxi 330006, P.R. China, Jiangxi Institute of Respiratory Disease, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Department of Geriatrics, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Department of Urology, The Second Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang 310009, P.R. China, Jiangxi Institute of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China
Published online on: April 13, 2020 https://doi.org/10.3892/ijo.2020.5043
Pages: 139-150
Copyright: © Yu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prostate cancer (PCa) is the second leading cause of cancer‑related death among men worldwide. The present study aimed to investigate the role of germ cell‑specific gene 2 protein (GSG2), also termed histone H3 phosphorylated by GSG2 at threonine‑3, in the development and progression of PCa. GSG2 expression levels in PCa tissues and para‑carcinoma tissues was detected by immunohistochemistry. The GSG2 knockdown cell model was constructed by lentivirus infection, and the knockdown efficiency was verified by qPCR and WB. In addition, the effects of shGSG2 on cell proliferation, colony formation and apoptosis were evaluated by Celigo cell counting assay, Giemsa staining and flow cytometry, respectively. Tumor development in nude mice was also detected. GSG2 expression was upregulated in PCa tissues and human PCa cell lines PC‑3 and DU 145. High expression of GSG2 in tumor samples was associated with progressed tumors. GSG2 knockdown suppressed cell proliferation and colony formation, but promoted apoptosis, which was also verified in vivo. The results of the present study revealed that GSG2 upregulation was associated with PCa progression; GSG2 knockdown inhibited cell proliferation and colony formation and induced apoptosis, and may therefore serve as a potential therapeutic target for PCa therapy.

View Figures

View References

1	Weng CC, Ding PY, Liu YH, Hawse JR, Subramaniam M, Wu CC, Lin YC, Chen CY, Hung WC and Cheng KH: Mutant Kras induced upregulation of CD24 enhances prostate cancer stemness and bone metastasis. Oncogene. 38:2005–2019. 2019. View Article : Google Scholar
2	Rawla P: Epidemiology of prostate cancer. World J Oncol. 10:63–89. 2019. View Article : Google Scholar : PubMed/NCBI
3	Fong LY, Jing R, Smalley KJ, Wang ZX, Taccioli C, Fan S, Chen H, Alder H, Huebner K, Farber JL, et al: Human like hyper plastic prostate with low ZIP1 induced solely by Zn deficiency in rats. Proc Natl Acad Sci USA. 115:E11091–E11100. 2018. View Article : Google Scholar
4	Barry MJ and Simmons LH: Prevention of prostate cancer morbidity and mortality: Primary prevention and early detection. Med Clin North Am. 101:787–806. 2017. View Article : Google Scholar : PubMed/NCBI
5	Daniyal M, Siddiqui ZA, Akram M, Asif HM, Sultana S and Khan A: Epidemiology, etiology, diagnosis and treatment of prostate cancer. Asian Pac J Cancer Prev. 15:9575–9578. 2014. View Article : Google Scholar : PubMed/NCBI
6	Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L, et al: Prevention and early detection of prostate cancer. Lancet Oncol. 15:e484–e492. 2014. View Article : Google Scholar : PubMed/NCBI
7	Pezaro C, Woo HH and Davis ID: Prostate cancer: Measuring PSA. Intern Med J. 44:433–440. 2014. View Article : Google Scholar : PubMed/NCBI
8	Mohamad NV, Soelaiman IN and Chin KY: A review on the effects of androgen deprivation therapy (ADT) on bone health status in men with prostate cancer. Endocr Metab Immune Disord Drug Targets. 17:276–284. 2017. View Article : Google Scholar : PubMed/NCBI
9	Munkley J, Vodak D, Livermore KE, James K, Wilson BT, Knight B, Mccullagh P, Mcgrath J, Crundwell M, Harries LW, et al: Glycosylation is an androgen regulated process essential for prostate cancer cell viability. EBioMedicine. 8:103–116. 2016. View Article : Google Scholar : PubMed/NCBI
10	Reina Campos M, Linares JF, Duran A, Cordes T, L'Hermitte A, Badur MG, Bhangoo MS, Thorson PK, Richards A, Rooslid T, et al: Increased serine and one carbon pathway metabolism by PKClambda/iota deficiency promotes neuroendo crine prostate cancer. Cancer Cell. 35:385–400.e9. 2019. View Article : Google Scholar
11	Xu K, Ganapathy K, Andl T, Wang Z, Copland JA, Chakrabarti R and Florczyk SJ: 3D porous chitosan-alginate scaffold stiffness promotes differential responses in prostate cancer cell lines. Biomaterials. 217:1193112019. View Article : Google Scholar : PubMed/NCBI
12	Dai J, Sultan S, Taylor SS and Higgins JM: The kinase haspin is required for mitotic histone H3 Thr 3 phosphorylation and normal metaphase chromosome alignment. Genes Dev. 19:472–488. 2005. View Article : Google Scholar : PubMed/NCBI
13	Kestav K, Uri A and Lavogina D: Structure, Roles and inhibi tors of a mitotic protein kinase haspin. Curr Med Chem. 24:2276–2293. 2017. View Article : Google Scholar
14	Opoku Temeng C, Dayal N, Aflaki Sooreshjani M and Sintim HO: 3H-pyrazolo[4,3-f]quinoline haspin kinase inhibi tors and anticancer properties. Bioorg Chem. 78:418–426. 2018. View Article : Google Scholar
15	Lavogina D, Kestav K, Chaikuad A, Heroven C, Knapp S and Uri A: Co crystal structures of the protein kinase haspin with bisubstrate inhibitors. Acta Crystallogr F Struct Biol Commun. 72:339–345. 2016. View Article : Google Scholar : PubMed/NCBI
16	Kim JE, Lee SY, Jang M, Choi HK, Kim JH, Chen H, Lim TG, Dong Z and Lee KW: Coumestrol epigenetically suppresses cancer cell proliferation: Coumestrol is a natural haspin kinase inhibitor. Int J Mol Sci. 18:pii: E2228. 2017. View Article : Google Scholar
17	Amoussou NG, Bigot A, Roussakis C and Robert JH: Haspin: A promising target for the design of inhibitors as potent anticancer drugs. Drug Discov Today. 23:409–415. 2018. View Article : Google Scholar
18	Han L, Wang P, Sun Y, Liu S and Dai J: Anti melanoma activi ties of haspin inhibitor CHR 6494 deployed as a single agent or in a synergistic combination with MEK inhibitor. J Cancer. 8:2933–2943. 2017. View Article : Google Scholar :
19	Scheff NN, Alemu RG, Klares R III, Wall IM, Yang SC, Dolan JC and Schmidt BL: Granulocyte colony stimulating factor induced neutrophil recruitment provides opioid mediated endogenous anti-nociception in female mice with oral squamous cell carci noma. Front Mol Neurosci. 12:2172019. View Article : Google Scholar
20	Pfaffl MW: Pfaffl A new mathematical model for relative quan tification in real-time RT-PCR. Nucleic Acids Res. 29:e452001. View Article : Google Scholar
21	Metzger E, Wang S, Urban S, Willmann D, Schmidt A, Offermann A, Allen A, Sum M, Obier N, Cottard F, et al: KMT9 monomethylates histone H4 lysine 12 and controls proliferation of prostate cancer cells. Nat Struct Mol Biol. 26:361–371. 2019. View Article : Google Scholar : PubMed/NCBI
22	Fong KW, Zhao JC, Song B, Zheng B and Yu J: TRIM28 protects TRIM24 from SPOP mediated degradation and promotes pros tate cancer progression. Nat Commun. 9:50072018. View Article : Google Scholar
23	Canesin G, Evans Axelsson S, Hellsten R, Sterner O, Krzyzanowska A, Andersson T and Bjartell A: The STAT3 inhibitor galiellalactone effectively reduces tumor growth and metastatic spread in an orthotopic xenograft mouse model of prostate cancer. Eur Urol. 69:400–404. 2016. View Article : Google Scholar
24	Wang Z, Wang Y, Zhu S, Liu Y, Peng X, Zhang S, Zhang Z, Qiu Y, Jin M, Wang R, et al: DT 13 inhibits proliferation and metastasis of human prostate cancer cells through blocking PI3K/Akt pathway. Front Pharmacol. 9:14502018. View Article : Google Scholar
25	Maiolica A, de Medina Redondo M, Schoof EM, Chaikuad A, Villa F, Gatti M, Jeganathan S, Lou HJ, Novy K, Hauri S, et al: Modulation of the chromatin phosphoproteome by the Haspin protein kinase. Mol Cell Proteomics. 13:1724–1740. 2014. View Article : Google Scholar : PubMed/NCBI
26	Patnaik D, Jun X, Glicksman MA, Cuny GD, Stein RL and Higgins JM: Identification of small molecule inhibitors of the mitotic kinase haspin by high throughput screening using a homogeneous time resolved fluorescence resonance energy transfer assay. J Biomol Screen. 13:1025–1034. 2008. View Article : Google Scholar : PubMed/NCBI
27	Balzano D, Santaguida S, Musacchio A and Villa F: A general framework for inhibitor resistance in protein kinases. Chem Biol. 18:966–975. 2011. View Article : Google Scholar : PubMed/NCBI
28	Wang F, Ulyanova NP, Daum JR, Patnaik D, Kateneva AV, Gorbsky GJ and Higgins JM: Haspin inhibitors reveal centro meric functions of Aurora B in chromosome segregation. J Cell Biol. 199:251–268. 2012. View Article : Google Scholar : PubMed/NCBI
29	Li S, Wu Z, Ma P, Xu Y, Chen Y, Wang H, He P, Kang Z, Yin L, Zhao Y, et al: Ligand dependent EphA7 signaling inhibits pros tate tumor growth and progression. Cell Death Dis. 8:e31222017. View Article : Google Scholar
30	Zabala Letona A, Arruabarrena Aristorena A, Martín Martín N, Fernandez-Ruiz S, Sutherland JD, Clasquin M, Tomas-Cortazar J, Jimenez J, Torres I, Quang P, et al: mTORC1 dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. Nature. 547:109–113. 2017. View Article : Google Scholar
31	Jing X, Sonoki T, Miyajima M, Sawada T, Terada N, Takemura S and Sakaguchi K: EphA4 deleted microenvironment regulates cancer development and leukemoid reaction of the isografted 4T1 murine breast cancer via reduction of an IGF1 signal. Cancer Med. 5:1214–1227. 2016. View Article : Google Scholar : PubMed/NCBI
32	Li S, Zhu Y, Ma C, Qiu Z, Zhang X, Kang Z, Wu Z, Wang H, Xu X, Zhang H, et al: Downregulation of EphA5 by promoter methylation in human prostate cancer. BMC Cancer. 15:182015. View Article : Google Scholar : PubMed/NCBI
33	Li S, Ma Y, Xie C, Wu Z, Kang Z, Fang Z, Su B and Guan M: EphA6 promotes angiogenesis and prostate cancer metastasis and is associated with human prostate cancer progression. Oncotarget. 6:22587–22597. 2015. View Article : Google Scholar : PubMed/NCBI
34	Ivanova IA, Vermeulen JF, Ercan C, Houthuijzen JM, Saig FA, Vlug EJ, van der Wall E, van Diest PJ, Vooijs M and Derksen PW: FER kinase promotes breast cancer metastasis by regulating α6 and β1 integrin dependent cell adhesion and anoikis resistance. Oncogene. 32:5582–5592. 2013. View Article : Google Scholar : PubMed/NCBI
35	Vishwamitra D, George SK, Shi P, Kaseb AO and Amin HM: Type I insulin like growth factor receptor signaling in hemato logical malignancies. Oncotarget. 8:1814–1844. 2017. View Article : Google Scholar
36	Jay J, Hammer A, Nestor Kalinoski A and Diakonova M: JAK2 tyrosine kinase phosphorylates and is negatively regulated by centrosomal protein Ninein. Mol Cell Biol. 35:111–131. 2015. View Article : Google Scholar :
37	Roll JD and Reuther GW: ALK activating homologous mutations in LTK induce cellular transformation. PLoS One. 7:e317332012. View Article : Google Scholar
38	Prchal-Murphy M, Witalisz-Siepracka A, Bednarik KT, Putz EM, Gotthardt D, Meissl K, Sexl V, Müller M and Strobl B: In vivo tumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity. Oncoimmunology. 4:e10475792015. View Article : Google Scholar :